+65 3158 9940
1300 798 820
+64 9801 0299
Melbourne, Australia , 20 June 2012 – A new therapy to treat a common hospital superbug* infection Clostridium difficile, will soon be available to Australian & New Zealand patients. Melbourne biopharmaceutical company Specialised Therapeutics Australia Pty, Ltd. (STA) has entered into an exclusive distribution & license agreement with US based Optimer Pharmaceuticals, Inc. (Optimer) to develop and
Associate Professor Gary Richardson is the Director of Oncology Clinics Victoria, Director of Cabrini Academic Haematology and Oncology Services and an Associate Professor of Medicine at Monash University. He previously held the position of Director, Department of Medical Oncology and Clinical Haematology at Monash Medical Centre. He is a Fellow of the Royal Australasian
Our company has enjoyed a long-standing relationship with Rare Cancers Australia, supporting this organisation’s ongoing endeavour to provide all cancer patients with timely and affordable access to new cancer therapies. We are proud to introduce guest blogger Richard Vines, the CEO and co-founder of RCA, as he passionately but simply explains the need for